Introduction {#j_bjmg-2019-0012_s_001}
============

Tetrasomy 9p is a rare chromosomal abnormality characterized by the presence of four copies of the short ρ arm of chromosome 9. Occasionally, a minute portion of the long q arm is duplicated as well. The common mechanism associated with formation of tetrasomy 9p seems to be meiosis II non disjunction of maternal origin, followed by meiotic or postmeiotic mitotic misdivision or recombination leading to duplication with subsequent loss of the q arm of chromosome 9 \[[@j_bjmg-2019-0012_ref_001]\].

Tetrasomy 9p was first described by Ghymers *et al*. \[[@j_bjmg-2019-0012_ref_002]\] in 1973 in a child with multiple abnormalities, where classic karyotype analysis revealed tetrasomy 9p in lymphocytes, but not in fibroblasts. The first prenatal case of tetrasomy 9p was published by Schaefer *et al*. \[[@j_bjmg-2019-0012_ref_003]\] in 1991, where the chromosomal abnormality was detected in cord blood lymphocytes in a fetus with multiple anomalies, including dolichocephaly with hydrocephalus, possible spinal dysraphism, absent kidneys and bladder, severe oligohydraminos and intrauterine growth retardation.

Especially in the later years, the detection rate of tetrasomy 9p increased with better fetal monitoring and more accessible prenatal diagnostics. Fourteen cases were reported in last 3 years \[[@j_bjmg-2019-0012_ref_004],[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_006],[@j_bjmg-2019-0012_ref_007]\], detected using microarrays in comparison with 53 cases reported from 1973 to 2015 using GTG banding and/or fluorescent *in situ* hybridization (FISH), analysis \[[@j_bjmg-2019-0012_ref_001],[@j_bjmg-2019-0012_ref_002],[@j_bjmg-2019-0012_ref_003],[@j_bjmg-2019-0012_ref_008], [@j_bjmg-2019-0012_ref_009], [@j_bjmg-2019-0012_ref_010], [@j_bjmg-2019-0012_ref_011], [@j_bjmg-2019-0012_ref_012], [@j_bjmg-2019-0012_ref_013], [@j_bjmg-2019-0012_ref_014], [@j_bjmg-2019-0012_ref_015], [@j_bjmg-2019-0012_ref_016], [@j_bjmg-2019-0012_ref_017], [@j_bjmg-2019-0012_ref_018], [@j_bjmg-2019-0012_ref_019], [@j_bjmg-2019-0012_ref_020], [@j_bjmg-2019-0012_ref_021], [@j_bjmg-2019-0012_ref_022], [@j_bjmg-2019-0012_ref_023], [@j_bjmg-2019-0012_ref_024], [@j_bjmg-2019-0012_ref_025], [@j_bjmg-2019-0012_ref_026], [@j_bjmg-2019-0012_ref_027], [@j_bjmg-2019-0012_ref_028], [@j_bjmg-2019-0012_ref_029], [@j_bjmg-2019-0012_ref_030], [@j_bjmg-2019-0012_ref_031], [@j_bjmg-2019-0012_ref_032], [@j_bjmg-2019-0012_ref_033], [@j_bjmg-2019-0012_ref_034], [@j_bjmg-2019-0012_ref_035], [@j_bjmg-2019-0012_ref_036], [@j_bjmg-2019-0012_ref_037], [@j_bjmg-2019-0012_ref_038], [@j_bjmg-2019-0012_ref_039], [@j_bjmg-2019-0012_ref_040], [@j_bjmg-2019-0012_ref_041], [@j_bjmg-2019-0012_ref_042], [@j_bjmg-2019-0012_ref_043], [@j_bjmg-2019-0012_ref_044], [@j_bjmg-2019-0012_ref_045], [@j_bjmg-2019-0012_ref_046], [@j_bjmg-2019-0012_ref_047], [@j_bjmg-2019-0012_ref_048], [@j_bjmg-2019-0012_ref_049], [@j_bjmg-2019-0012_ref_050], [@j_bjmg-2019-0012_ref_051], [@j_bjmg-2019-0012_ref_052]\].

The objective of this review was to highlight the importance of early fetal ultrasound screening in identifying rare chromosomal abnormalities and to present the array comparative genomic hybridization (aCGH) as a valuable clinical diagnostic tool that allows rapid and precise identification of chromosomal abnormalities. The purpose of this study was a comprehensive review of the literature regarding prenatal tetrasomy 9p syndrome with comparison of fetal abnormalities seen in different stages of fetal development. In addition, the comparison of mosaic *vs*. non mosaic forms of tetrasomy 9p is presented, with the focus on the differences in the clinical presentation between both groups, correlation of the level of mosaicism with the phenotype and diagnostic challenges related to mosaic cases.

Materials, methods and data source {#j_bjmg-2019-0012_s_002}
==================================

**Literature Search**. A PubMed database search was performed without any publication date or journal restriction with the following key words: tetrasomy 9p, isochro-mosome 9p, mosaic tetrasomy 9p, tetrasomy 9p prenatal, duplication 9p prenatal and trisomy 9p prenatal. All cases describing a prenatally-detected tetrasomy 9p were hand-searched for relevant information with the focus on the gestational age at the time of diagnosis, the type(s) and results of genetic diagnostic tests, ultrasound findings, pregnancy outcome and confirmatory studies. Secondly, we chose the key words trisomy 9p and duplication 9p to divide and compare the severity of the clinical picture, depending on the 9p copy number/gene dosage effect (trisomy 9p *vs*. tetrasomy 9p).

**Methodology**. In addition to previously reported cases of tetrasomy 9p, we added a prenatally discovered case of tetrasomy 9p at the Clinical Institute of Medical Genetics, University Medical Centre Ljubljana (UMCL), Ljubljana, Slovenia. It was detected using microarray analysis (60K aCGH; Agilent Technologies, Santa Clara, CA, USA), after increased nuchal translucency (NT) of 4.1 mm at the gestational age 12^+0^ weeks and chorionic villus sampling. Additionally, the GTG banding and FISH analysis with probes Vysis TelVyson 9p SG, TelVyson 9q SO and CEP 9 Saq (Abbott Molecular; Abbott Laboratories, Chicago, IL, USA), were used for confirmation of tetrasomy 9p. Additional anomalies including facial dysmorphism, cleft lip/palate and genitourinary abnormalities were detected with ultrasound at the gestational age 15^+1^ weeks.

Results {#j_bjmg-2019-0012_s_003}
=======

A total of 85 articles were matched to selected key words. After applying selected criteria, 21 cases of prenatally detected tetrasomy 9p in 18 different publications remained for detailed analysis. We added our prenatal case, resulting in 22 cases altogether. Of these, 15 cases were related to full tetrasomy 9p and seven cases were a mosaic form of tetrasomy 9p. A further four publications were identified describing trisomy 9p detected prenatally and were suitable for comparison of tetrasomy 9p and trisomy 9p phenotype \[[@j_bjmg-2019-0012_ref_053], [@j_bjmg-2019-0012_ref_054], [@j_bjmg-2019-0012_ref_055], [@j_bjmg-2019-0012_ref_056]\].

Altogether, most of the reported cases of tetrasomy 9p were associated with severe congenital abnormalities. The most common prenatally detected features of tetrasomy 9p were central nervous system (CNS) abnormalities (13/22) (our case \[[@j_bjmg-2019-0012_ref_003],[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_015],[@j_bjmg-2019-0012_ref_032],[@j_bjmg-2019-0012_ref_033],[@j_bjmg-2019-0012_ref_037], [@j_bjmg-2019-0012_ref_038], [@j_bjmg-2019-0012_ref_039], [@j_bjmg-2019-0012_ref_040],[@j_bjmg-2019-0012_ref_045],[@j_bjmg-2019-0012_ref_047]\]), limb/ skeletal malformations (11/22) (our case \[[@j_bjmg-2019-0012_ref_001],[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_032],[@j_bjmg-2019-0012_ref_038], [@j_bjmg-2019-0012_ref_039], [@j_bjmg-2019-0012_ref_040],[@j_bjmg-2019-0012_ref_045],[@j_bjmg-2019-0012_ref_047],[@j_bjmg-2019-0012_ref_051])\], intrauterine growth retardation (IUGR) (10/22) \[[@j_bjmg-2019-0012_ref_001],[@j_bjmg-2019-0012_ref_003], [@j_bjmg-2019-0012_ref_004], [@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_033], [@j_bjmg-2019-0012_ref_038],[@j_bjmg-2019-0012_ref_039],[@j_bjmg-2019-0012_ref_046]\], cleft lip and/or palate (10/22) (our case \[[@j_bjmg-2019-0012_ref_001],[@j_bjmg-2019-0012_ref_005], [@j_bjmg-2019-0012_ref_032],[@j_bjmg-2019-0012_ref_038],[@j_bjmg-2019-0012_ref_039],[@j_bjmg-2019-0012_ref_045], [@j_bjmg-2019-0012_ref_046], [@j_bjmg-2019-0012_ref_047])\], and facial dysmorphism (8/22) (our case \[[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_039],[@j_bjmg-2019-0012_ref_040],[@j_bjmg-2019-0012_ref_045],[@j_bjmg-2019-0012_ref_046])\]. All the details and less common anomalies are presented in [Tables 1](#j_bjmg-2019-0012_tab_001){ref-type="table"} and [2](#j_bjmg-2019-0012_tab_002){ref-type="table"}.

###### 

Prentally detected abnormalities of 22 cases of tetrasomy 9p.

  --------------------------------- -------------------- ------------------- ------------ --------------- ------------------- ------------------------------- -------------------------- ---------------------------------
  Refs.                             Facial Dysmorphism   Cleft Lip/ Palate   IUGR         CNS Anomalies   Cardiac Anomalies   Genitourinary Tract Anomalies   Skeletal/ Limb Anomalies   Amniotic Fluid Volume Anomalies
  Our case                          \[+\]                \[+\]               **\[--\]**   **\[--\]**      **\[--\]**          \[+\]                           \[+\]                      **\[--\]**
  \[[@j_bjmg-2019-0012_ref_005]\]   \[+\]                \[+\]               **\[--\]**   **\[--\]**      **\[--\]**          **\[-\]**                       \[+\]                      **\[--\]**
  \[[@j_bjmg-2019-0012_ref_005]\]   \[+\]                **\[--\]**          **\[+\]**    \[+\]           **\[--\]**          \[+\]                           **\[--\]**                 **\[--\]**
  \[[@j_bjmg-2019-0012_ref_006]\]   \[+\]                **\[--\]**          **\[+\]**    \[+\]           **\[--\]**          **\[--\]**                      \[+\]                      \[+\]
  \[[@j_bjmg-2019-0012_ref_052]\]   **\[--\]**           **\[--\]**          **\[--\]**   **\[--\]**      \[+\]               **\[--\]**                      **\[--\]**                 **\[--\]**
  \[[@j_bjmg-2019-0012_ref_051]\]   **\[--\]**           **\[--\]**          **\[--\]**   **\[--\]**      **\[--\]**          **\[--\]**                      \[+\]                      **\[--\]**
  \[[@j_bjmg-2019-0012_ref_004]\]   **\[--\]**           **\[--\]**          **\[+\]**    **\[--\]**      **\[--\]**          **\[--\]**                      **\[--\]**                 **\[--\]**
  \[[@j_bjmg-2019-0012_ref_045]\]   **\[+\]**            **\[+\]**           **\[--\]**   \[+\]           **\[--\]**          \[+\]                           **\[+\]**                  **\[--\]**
  \[[@j_bjmg-2019-0012_ref_039]\]   **\[+\]**            **\[+\]**           **\[+\]**    \[+\]           \[+\]               \[+\]                           **\[+\]**                  \[+\]
  \[[@j_bjmg-2019-0012_ref_034]\]   **\[--\]**           **\[--\]**          **\[--\]**   **\[--\]**      **\[--\]**          **\[--\]**                      **\[--\]**                 **\[--\]**
  \[[@j_bjmg-2019-0012_ref_046]\]   \[+\]                \[+\]               **\[+\]**    **\[--\]**      **\[--\]**          **\[--\]**                      **\[+\]**                  \[+\]
  \[[@j_bjmg-2019-0012_ref_040]\]   \[+\]                **\[--\]**          **\[--\]**   \[+\]           \[+\]               **\[--\]**                      **\[+\]**                  \[+\]
  \[[@j_bjmg-2019-0012_ref_037]\]   **\[--\]**           **\[--\]**          **\[--\]**   \[+\]           **\[--\]**          \[+\]                           **\[--\]**                 **\[--\]**
  \[[@j_bjmg-2019-0012_ref_047]\]   **\[--\]**           \[+\]               **\[--\]**   \[+\]           **\[--\]**          **\[--\]**                      **\[+\]**                  **\[--\]**
  \[[@j_bjmg-2019-0012_ref_033]\]   **\[--\]**           **\[--\]**          \[+\]        \[+\]           **\[--\]**          **\[--\]**                      **\[--\]**                 **\[--\]**
  \[[@j_bjmg-2019-0012_ref_038]\]   **\[--\]**           \[+\]               **\[--\]**   **\[--\]**      \[+\]               **\[--\]**                      \[+\]                      **\[--\]**
  \[[@j_bjmg-2019-0012_ref_038]\]   **\[--\]**           \[+\]               **\[+\]**    \[+\]           **\[--\]**          **\[--\]**                      **\[--\]**                 **\[--\]**
  \[[@j_bjmg-2019-0012_ref_001]\]   **\[--\]**           \[+\]               **\[+\]**    **\[--\]**      **\[--\]**          **\[-\]**                       **\[--\]**                 **\[--\]**
  \[[@j_bjmg-2019-0012_ref_001]\]   **\[--\]**           **\[--\]**          **\[+\]**    **\[--\]**      **\[--\]**          **\[-\]**                       \[+\]                      \[+\]
  \[[@j_bjmg-2019-0012_ref_032]\]   **\[--\]**           **\[+\]**           **\[--\]**   \[+\]           \[+\]               \[+\]                           \[+\]                      **\[--\]**
  \[[@j_bjmg-2019-0012_ref_003]\]   **\[--\]**           **\[--\]**          **\[+\]**    \[+\]           **\[--\]**          \[+\]                           **\[--\]**                 \[+\]
  \[[@j_bjmg-2019-0012_ref_015]\]   **\[--\]**           **\[--\]**          **\[--\]**   \[+\]           **\[--\]**          **\[--\]**                      **\[--\]**                 **\[--\]**
  --------------------------------- -------------------- ------------------- ------------ --------------- ------------------- ------------------------------- -------------------------- ---------------------------------

IUGR: intrauterine growth retardation; CNS: central nervous system; \[+\]: present; \[--\]: not present.

###### 

Detailed karyotype results in prenatally detected cases of tetrasomy 9p.

  Refs.                              Karyotype                                                                                                                                          Molecular Karyotype                                                                                          Confirmatory Studies
  ---------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ --------------------------
  Our case                           CVS: 47, +i(9p)(ql3) = 100.0% \[[Figure 1(a)](#j_bjmg-2019-0012_fig_001){ref-type="fig"} and [1(b)\]](#j_bjmg-2019-0012_fig_001){ref-type="fig"}   arr\[hgl9\] 9p24.3pl3.2(204,193-38,815,475)x4 \[[Figure 1(c)\]](#j_bjmg-2019-0012_fig_001){ref-type="fig"}   muscle: 100.0%
  \[[@j_bjmg-2019-0012_ref_051]\]?   CVS: +i(9p) = 100.0%                                                                                                                               **--**                                                                                                       no
  \[[@j_bjmg-2019-0012_ref_001]\]    CVS: 47,XY,+i(9p) = 100.0%; AC: 47,XY,+i(9p)                                                                                                       --                                                                                                           no
  \[[@j_bjmg-2019-0012_ref_004]\]    CVS: 47,XY,+i(9p)(ql2) = 100.0%; AC: 47,XY,+i(9p)(ql2) = 100.0%                                                                                    --                                                                                                           
  \[[@j_bjmg-2019-0012_ref_037]\]    CVS: 47,XY,+i(9p)(ql2) = 100.0%; AC: 47,XY,+i(9p)(ql2) = 100.0%                                                                                    --                                                                                                           no
                                                                                                                                                                                        arr\[hgl9\] 19p24.3qll(214,367-                                                                              
  \[[@j_bjmg-2019-0012_ref_005]\]    CVS: +i(9p) = 100.0%; AC: +i(9p) = 100.0%                                                                                                          39,816,368)x4                                                                                                liver: 100.0%
  \[[@j_bjmg-2019-0012_ref_045]\]    AC: 47,XY,+i(9p)= 100.0%                                                                                                                           --                                                                                                           no
  \[[@j_bjmg-2019-0012_ref_039]\]    AC: 47,XY,+i(9p)(ql3) = 100.0%                                                                                                                     --                                                                                                           no
  \[[@j_bjmg-2019-0012_ref_046]\]    AC: 47,XY,+i(9p)= 100.0%                                                                                                                           --                                                                                                           no
                                                                                                                                                                                                                                                                                                     blood: 95.0%;
  \[[@j_bjmg-2019-0012_ref_047]\]    AC: 47,XX,+i(9p) = 100.0%                                                                                                                          --                                                                                                           cord blood:
                                                                                                                                                                                                                                                                                                     85.0%
  \[[@j_bjmg-2019-0012_ref_038]\]    AC:47,+i(9p) = 96.3%                                                                                                                               --                                                                                                           no
                                                                                                                                                                                                                                                                                                     cord blood,
  \[[@j_bjmg-2019-0012_ref_038]\]    AC:47,+i(9p)=100.0%                                                                                                                                --                                                                                                           lung, placenta:
                                                                                                                                                                                                                                                                                                     100.0%
  \[[@j_bjmg-2019-0012_ref_001]\]    AC:47,XY,+i(9p) = 96.7%                                                                                                                            --                                                                                                           no
  \[[@j_bjmg-2019-0012_ref_032]\]    AC:47,+i(9p)=100.0%                                                                                                                                --                                                                                                           no
  \[[@j_bjmg-2019-0012_ref_015]\]    AC: 47,XY,+i(9p)= 100.0%                                                                                                                           --                                                                                                           no
                                     AC: 47,XX,+i(9p)(ql2) = 20.0%;                                                                                                                                                                                                                                  skin, lung:
  \[[@j_bjmg-2019-0012_ref_034]\]    Repeat AC: 47,XX,+i(9p)(ql2) = 16.7%                                                                                                                                                                                                                            0.0%; cord
                                                                                                                                                                                                                                                                                                     blood: 48.0%
  \[[@j_bjmg-2019-0012_ref_005]\]    AC:+i(9p) = 72.0%                                                                                                                                  --                                                                                                           fetal lung
  \[[@j_bjmg-2019-0012_ref_006]\]    AC: 47,XX,+i(9pXql2) = 100.0%                                                                                                                      9p24.3-pl3.1 (38,55 Mb)                                                                                      no
                                     AC: 47,XX,+i(9pXql2) = 21.4%; Repeat AC: 47,XX,+i(pXq21.11) = 16.7%;                                                                               arr(hgl9) 9p24.3pl3.1 (0-40,450,202)x3.4;                                                                    fetal bloo±
  \[[@j_bjmg-2019-0012_ref_004]\]    FISH (on cultured amniocytes): 47,XX,+i(9p)(q21.11) = 47.1%                                                                                        9pl3.1q21.11(40.576.977-71.026.063)x3                                                                        32.5%
  \[[@j_bjmg-2019-0012_ref_052]\]    AC: 47,XX,+i(9pXql2) = 15.8%; Cord blood: 47,XX,+i(9p) = 59.7%                                                                                     --                                                                                                           skin: lung: 24.016.0%; %
  \[[@j_bjmg-2019-0012_ref_033]\]    AC: 47,XX,+i(9p)(ql3) =50.0%; Cord blood: 47,XX,+i(9p)(ql3) = 25.0%                                                                                --                                                                                                           peripheral
                                                                                                                                                                                                                                                                                                     blood: 75.3%
  \[[@j_bjmg-2019-0012_ref_003]\]    Cordocentesis: 47,XX,+i(9p) = 100.0%                                                                                                               --                                                                                                           skin: 100.0%

CVS: chorionic villus sampling; AC: amniocentesis; FISH: fluoresent *in situ* hybridization.

![Prenatal genetic analysis reported additional cases of tetrasomy 9p. (A) Fetal karyotype analysis revealed two normal chromosomes 9 and additional i(9p). (B) Fluorescent *in situ* hybridization using Vysis (Abbott Laboratories) probes: TelVyson 9p SG and TelVyson 9q SO and Vysis CEP 9 SAq. Isochromosome 9p is marked with an arrow. (C) Microarray analysis, revealing four copies of 9p.](bjmg-22-011-g001){#j_bjmg-2019-0012_fig_001}

The type of fetal anomalies were further analyzed related to fetal gestational age at their discovery (details are presented in [Table 3](#j_bjmg-2019-0012_tab_003){ref-type="table"}). A total of six cases of tetrasomy 9p were detected in the first trimester based on abnormal

###### 

Prenatally detected (ultrasound assessment), abnormalities in the case of full tetrasomy 9p (full) and mosaic tetrasomy 9p (mosaic), according to the pregnancy trimester.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                         First Trimester                                                                                             Second Trimester                                                                                                                                                                       Third Trimester                                                        Unspecified Time
  --------------------------------- ----------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  CNS anomalies                     --                                                                                                          6 full \[[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_015],[@j_bjmg-2019-0012_ref_032],[@j_bjmg-2019-0012_ref_037],[@j_bjmg-2019-0012_ref_039],[@j_bjmg-2019-0012_ref_045]\];\   2 full \[[@j_bjmg-2019-0012_ref_003],[@j_bjmg-2019-0012_ref_040]\]     2 full \[[@j_bjmg-2019-0012_ref_038],[@j_bjmg-2019-0012_ref_047]\]
                                                                                                                                                2 mosaic \[[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_033]\]                                                                                                                                                                                          

  Cardiac anomalies                 --                                                                                                          2 full \[[@j_bjmg-2019-0012_ref_032],[@j_bjmg-2019-0012_ref_039]\];\                                                                                                                   1 full \[[@j_bjmg-2019-0012_ref_040]\]                                 1 mosaic \[[@j_bjmg-2019-0012_ref_048]\]
                                                                                                                                                1 mosaic \[[@j_bjmg-2019-0012_ref_052]\]                                                                                                                                                                                                                      

  IUGR                              1 full \[[@j_bjmg-2019-0012_ref_001]\]                                                                      2 full \[[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_039];\                                                                                                                     5 full \[[@j_bjmg-2019-0012_ref_003]\];\                               5 full \[[@j_bjmg-2019-0012_ref_038],[@j_bjmg-2019-0012_ref_046]\];\
                                                                                                                                                2 mosaic \[[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_033]\]                                                                                                                   1 mosaic \[[@j_bjmg-2019-0012_ref_001]\]                               1 mosaic \[[@j_bjmg-2019-0012_ref_004]\]

  Skeletal/limb anomalies           2 full \[[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_051]\]                                          5 full (our case \[[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_032],[@j_bjmg-2019-0012_ref_039],[@j_bjmg-2019-0012_ref_045]\]                                                   1 full \[[@j_bjmg-2019-0012_ref_040]\];\                               1 full \[[@j_bjmg-2019-0012_ref_047]\];\
                                                                                                                                                                                                                                                                                                                                       2 mosaic\[[@j_bjmg-2019-0012_ref_001]\]                                1 mosaic \[[@j_bjmg-2019-0012_ref_038]\]

  Genitourinary tract anomalies     --                                                                                                          5 full (our \[case \[[@j_bjmg-2019-0012_ref_032],[@j_bjmg-2019-0012_ref_037],[@j_bjmg-2019-0012_ref_039],[@j_bjmg-2019-0012_ref_045]\];\                                               1 full \[[@j_bjmg-2019-0012_ref_003]\]                                 1 mosaic \[[@j_bjmg-2019-0012_ref_038]\]
                                                                                                                                                1 mosiac \[[@j_bjmg-2019-0012_ref_005]\]                                                                                                                                                                                                                      

  Facial dysmorphism                1 full \[[@j_bjmg-2019-0012_ref_005]\]                                                                      4 full (our case \[[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_039],[@j_bjmg-2019-0012_ref_045]\])                                                                              1 full \[[@j_bjmg-2019-0012_ref_040]\]                                 1 full \[[@j_bjmg-2019-0012_ref_046]\]

  Cleft lip/palate                  2 full \[[@j_bjmg-2019-0012_ref_001],[@j_bjmg-2019-0012_ref_005]\]                                          4 full (our case \[[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_049],[@j_bjmg-2019-0012_ref_045]\])                                                                              --                                                                     3 full \[[@j_bjmg-2019-0012_ref_038],[@j_bjmg-2019-0012_ref_046],[@j_bjmg-2019-0012_ref_047]\];\
                                                                                                                                                                                                                                                                                                                                                                                                              1 mosaic \[[@j_bjmg-2019-0012_ref_038]\]

  Amniotic fluid volume anomalies   --                                                                                                          2 full \[[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_039]\]                                                                                                                     2 full \[[@j_bjmg-2019-0012_ref_003],[@j_bjmg-2019-0012_ref_040]\];\   1 full \[[@j_bjmg-2019-0012_ref_046]\]
                                                                                                                                                                                                                                                                                                                                       1 mosaic \[[@j_bjmg-2019-0012_ref_001]\]                               

  Increased NT                      4 full (our case \[[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_039],[@j_bjmg-2019-0012_ref_045]\])   --                                                                                                                                                                                     --                                                                     --
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CNS: central nervous system; IUGR: intrauterine growth retardation; NT: nuchal translucency.

ultrasound assessment. The most common phenotypic feature was increased NT (4/6) (our case \[[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_039],[@j_bjmg-2019-0012_ref_045]\]), usually accompanied by at least one more anomaly (cleft lip and/or palate, skeletal abnormalities, IUGR, and facial dysmorphism). A single case presented with isolated increased NT only (our case). In the latter, chorionic villus sampling was performed after genetic counseling. Microarray analysis detected a tetrasomy 9p with 38.6 Mb four copies of the region 9p24.3pl3.2 (arr\[GRCh37\]9p24. 3pl3.1(204193_38815475)x4). The GTG banding and FISH analysis of 35 metaphase spreads revealed a pseudoisodicentric chromosome 9 consisting of the two ρ arms, two centromere regions and two q arm segments with a breakpoint at 9q13 (47,+psu idic(9)(q13) \[[Figure 1(A-C)\]](#j_bjmg-2019-0012_fig_001){ref-type="fig"}.

In 10 cases of tetrasomy 9p, the abnormal ultrasound findings were reported in the second trimester. The most common fetal anomalies were CNS abnormalities (8/10) \[[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_015],[@j_bjmg-2019-0012_ref_032],[@j_bjmg-2019-0012_ref_033],[@j_bjmg-2019-0012_ref_037],[@j_bjmg-2019-0012_ref_039],[@j_bjmg-2019-0012_ref_045]\], genitourinary tract anomalies (6/10) \[[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_032],[@j_bjmg-2019-0012_ref_037],[@j_bjmg-2019-0012_ref_039],[@j_bjmg-2019-0012_ref_045]\], skeletal/limb abnormalities (5/10) (our case) and facial dysmorphism (5/10) (our case \[[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_039], [@j_bjmg-2019-0012_ref_045]\]). Additional anomalies were discovered in less than five cases. An additional three cases were identified only after a third trimester ultrasound scan, presenting with IUGR and additional CNS and skeletal/limb abnormalities. For the remaining cases it was not possible to determine the precise time of the prenatal diagnosis (PND).

When comparing the genotype-phenotype correlation in the group of mosaic (seven cases) *vs*. full tetrasomy 9p (15 cases), less severe phenotypes were reported in mosaic cases, still including the same plethora of phenotypic features ([Table 3](#j_bjmg-2019-0012_tab_003){ref-type="table"}). The prenatally detected cases of tetrasomy 9p with lower levels of mosaicism presented with the involvement of only one organ system or without any major structural anomalies. One case presented with IUGR, the second with cardiac anomaly and the third with fetal ascites and hydrops fetalis. All mosaic cases were detected after amniocentesis \[[@j_bjmg-2019-0012_ref_001],[@j_bjmg-2019-0012_ref_004],[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_033],[@j_bjmg-2019-0012_ref_034],[@j_bjmg-2019-0012_ref_038],[@j_bjmg-2019-0012_ref_052]\], with the lowest level of mosaicism being 15.8% \[[@j_bjmg-2019-0012_ref_052]\] and the highest level of 96.7% \[[@j_bjmg-2019-0012_ref_001]\].

Lastly, we were interested in gene dosage effect, therefore, prenatal cases of tetrasomy 9p and trisomy 9p were compared \[[@j_bjmg-2019-0012_ref_053], [@j_bjmg-2019-0012_ref_054], [@j_bjmg-2019-0012_ref_055], [@j_bjmg-2019-0012_ref_056]\]. The clinical phenotype in trisomy 9p was similar to that described in tetrasomy 9p only milder.

Pregnancy outcome following PND of tetrasomy 9p were termination of pregnancy in 14/22 cases (our case \[[@j_bjmg-2019-0012_ref_004],[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_015],[@j_bjmg-2019-0012_ref_032],[@j_bjmg-2019-0012_ref_034],[@j_bjmg-2019-0012_ref_037],[@j_bjmg-2019-0012_ref_039],[@j_bjmg-2019-0012_ref_040],[@j_bjmg-2019-0012_ref_046],[@j_bjmg-2019-0012_ref_052]\]), neonatal death (3/22)

\[[@j_bjmg-2019-0012_ref_003],[@j_bjmg-2019-0012_ref_038],[@j_bjmg-2019-0012_ref_045]\], intrauterine death (1/22) \[[@j_bjmg-2019-0012_ref_001]\] and a child who survived to at least 4 years of age \[[@j_bjmg-2019-0012_ref_033]\] ([Table 4](#j_bjmg-2019-0012_tab_004){ref-type="table"}). For the remaining three cases this information was not provided. Only the mosaic forms of tetrasomy 9p survive past the neonatal period, whereas full tetrasomy 9p has a fatal outcome.

###### 

Pregnancy outcome after the prenatal diagnosis of tetrasomy 9p.

+-------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Pregnancy Outcome             | Number of Cases                                                                                                                                                                                                                                                |
+===============================+================================================================================================================================================================================================================================================================+
| Termination of pregnancy      | 10 full (our case \[[@j_bjmg-2019-0012_ref_001], [@j_bjmg-2019-0012_ref_005], [@j_bjmg-2019-0012_ref_007], [@j_bjmg-2019-0012_ref_032], [@j_bjmg-2019-0012_ref_037], [@j_bjmg-2019-0012_ref_039], [@j_bjmg-2019-0012_ref_040], [@j_bjmg-2019-0012_ref_046]\]); |
|                               |                                                                                                                                                                                                                                                                |
|                               | 4 mosaic \[[@j_bjmg-2019-0012_ref_004],[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_034],[@j_bjmg-2019-0012_ref_052]\]                                                                                                                                   |
+-------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Intrauterine death            | 1 mosaic (1)                                                                                                                                                                                                                                                   |
+-------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Neonatal death                | 3 full \[[@j_bjmg-2019-0012_ref_003],[@j_bjmg-2019-0012_ref_038],[@j_bjmg-2019-0012_ref_045]\]                                                                                                                                                                 |
+-------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Survival past neonatal period | 1 mosaic \[[@j_bjmg-2019-0012_ref_003]\]                                                                                                                                                                                                                       |
+-------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Unknown                       | 2 full \[[@j_bjmg-2019-0012_ref_047],[@j_bjmg-2019-0012_ref_051]\];\                                                                                                                                                                                           |
|                               | 1 mosaic \[[@j_bjmg-2019-0012_ref_038]\]                                                                                                                                                                                                                       |
+-------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

Discussion {#j_bjmg-2019-0012_s_004}
==========

Herein we reviewed all previously published prenatal cases of tetrasomy 9p available in the PubMed database, and included our unpublished case. To the best of our knowledge, our case is the first prenatal case where the tetrasomy 9p presented with an increased NT of 4.1 mm as the only phenotypic finding during the first trimester ultrasound scan. Our case was detected early in pregnancy and therefore other abnormalities, commonly associated with tetrasomy 9p, might not have been detected. Nevertheless, properly oriented counselling and early specific diagnosis provided sufficient information and support for the parents during their decision-making process.

Altogether, the most common prenatally detected features of tetrasomy 9p are CNS abnormalities (59%), limb/ skeletal malformations (50.0%), IUGR (45.0%), cleft lip and/or palate (45.0%). Additionally, facial dysmorphism, abnormality of the genitourinary system, abnormality of the amniotic fluid, and heart defects have also been described. This wide variability of clinical features in fetuses with tetrasomy 9p ([Tables 2](#j_bjmg-2019-0012_tab_002){ref-type="table"} and [3](#j_bjmg-2019-0012_tab_003){ref-type="table"}) might be explained by the difference of a mosaic *vs*. non-mosaic forms, the level of mosaicism, a limitation of chromosomal anomaly to certain tissues, and the size of the isochromosome 9p and Hsa9 genes presented in four copies \[[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_034],[@j_bjmg-2019-0012_ref_036],[@j_bjmg-2019-0012_ref_044]\].

The tissue-specific mosaicism was fully investigated in 5/7 prenatal mosaic cases \[[@j_bjmg-2019-0012_ref_004],[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_033],[@j_bjmg-2019-0012_ref_034],[@j_bjmg-2019-0012_ref_052]\], and it was suggested that this chromosomal rearrangement is better tolerated in lymphocytes compared to fibroblasts, amniocytes or chorionic villi (4,57), where the isochromosome was present with a lower frequency or not at all. Supporting this, there are considerably fewer cases of a mosaic form of tetrasomy 9p reported prenatally in comparison to full tetrasomy 9p. One might speculate that the loss of tetrasomy 9p cells in the long-term culture of mosaic cases is the main reason. This is supported with a report of false-negative prenatal cases \[[@j_bjmg-2019-0012_ref_004],[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_022],[@j_bjmg-2019-0012_ref_025],[@j_bjmg-2019-0012_ref_042]\]. With the application of microarray technology uncultured cells are analyzed, providing significant advantage over classical cytogenetic techniques (faster turn-around time, no need for culturing and losing mosaic tetrasomy 9p). Another plausible explanation for lower detection rate of mosaic forms of tetrasomy 9p might be a normal fetal ultrasound presentation of these cases during pregnancy \[[@j_bjmg-2019-0012_ref_007],[@j_bjmg-2019-0012_ref_022],[@j_bjmg-2019-0012_ref_025],[@j_bjmg-2019-0012_ref_042]\].

Interestingly, while comparing the trisomy 9p and tetrasomy 9p, we found that both syndromes have similar phenotype features but the clinical characteristics are much milder in trisomy 9p compared to tetrasomy 9p. This might be due to additional copy number of the whole 9p region in the tetrasomy 9p cases, but further cases of prenatal trisomy 9p need to be analyzed to make a conclusion.

Newer case reports of the tetrasomy 9p used high throughput techniques such as a comparative genomic hybridization, which has the ability to define the break points more accurately, thus improving the understanding of the genotype-phenotype correlation. The severity of the tetrasomy 9p phenotype increases with the involvement of the q arm; it was suggested that the presence of the 9q arm in the tetrasomic cases is related to the severity of cardiac malformations, intellectual disability and death, but the review was based on a small number of cases and/or the use of cytogenetic techniques without precise mapping of the breakpoint in earlier cases (5). We identified only three non-mosaic tetrasomy 9p prenatal cases that have been molecularly characterized by aCGH \[[@j_bjmg-2019-0012_ref_004],[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_007]\], and involved the 9q arm \[[@j_bjmg-2019-0012_ref_005],[@j_bjmg-2019-0012_ref_007]\]. Of the three, only one case had an additional gene involved within the amplified region of the q arm \[[@j_bjmg-2019-0012_ref_005]\], *i.e., CNTNAP3* gene (contactin associated protein-like 3, OMIM610517). The protein encoded by this gene belongs to the family of cell-recognition molecules. The family represents a subgroup of the neurexins. Neurexins have a role in the CNS as cell-surface receptors and their presence is important in neurotransmission and synapse formation. The exact function of *CNTNAP3* remains to be determined \[[@j_bjmg-2019-0012_ref_058]\].

There are still many factors to be elucidated that might play a role in the tetrasomy 9p phenotype; the contribution of each gene, a determination of the dosage-sensitive genes in 9p and/or 9q regions, the presence of presumably imprinted genes, a possible effect of the breakpoint on the disruption of gene regulation, and the unknown effect of involved non-coding regions. More cases discovered and characterized using genomic techniques and additional knowledge on the function of proteins involved will improve our understanding of the etiopathogenesis of the tetrasomy 9p disorder and offer the development of new therapeutic approaches.

Fetuses with increased NT measurements are at risk of having atypical chromosomal abnormalities in addition to the risk of common aneuploidies. Currently, noninvasive prenatal testing (NITP) is clinically validated for common aneuploidies only; these rare chromosomal abnormalities, such as tetrasomy 9p, are not optimally detectable by NIPT. A recent population study in Denmark revealed that among 193 638 pregnancies that underwent invasive testing, 11% of foetuses had abnormal karyotype \[[@j_bjmg-2019-0012_ref_059]\]. Of these, 23.4% phenotypically significant atypical chromosomal aberrations would be missed by currently available NIPT \[[@j_bjmg-2019-0012_ref_059]\]. Therefore, the invasive diagnostic testing with high throughput techniques such as aCGH is still the gold standard for fetuses with ultrasound anomalies enabling rapid and definite diagnosis.

In conclusion, an accurate and fast delivered genetic diagnosis in the prenatal setting allows the parents informed decision making. A pre-testing genetic counseling with the parents undergoing invasive procedure and genetic testing should also include rare, but clinically no less important, genomic findings, in addition to the common chromosome aberrations. The ultrasound measurement of NT remains an important marker for chromosome abnormalities even in the non-invasive prenatal screening era. However, neither ultrasound assessment nor first trimester screening can propose a definite diagnosis of tetrasomy 9p. The congenital anomalies of tetrasomy 9p show a considerable clinical variation, and the same anomalies are common in fetuses with a broad range of chromosome abnormalities, including trisomy 13, 18 and 21. An invasive genetic test is still needed for accurate diagnosis of chromosomal anomalies, including tetrasomy 9p.
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